151
|
Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary Malignancy Risk Following Proton Radiation Therapy. Front Oncol 2015; 5:261. [PMID: 26636040 PMCID: PMC4659915 DOI: 10.3389/fonc.2015.00261] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 11/09/2015] [Indexed: 01/17/2023] Open
Abstract
Radiation-induced secondary malignancies are a significant, yet uncommon cause of morbidity and mortality among cancer survivors. Secondary malignancy risk is dependent upon multiple factors including patient age, the biological and genetic predisposition of the individual, the volume and location of tissue irradiated, and the dose of radiation received. Proton therapy (PRT) is an advanced particle therapy with unique dosimetric properties resulting in reduced entrance dose and minimal to no exit dose when compared with standard photon radiation therapy. Multiple dosimetric studies in varying cancer subtypes have demonstrated that PRT enables the delivery of adequate target volume coverage with reduced integral dose delivered to surrounding tissues, and modeling studies taking into account dosimetry and radiation cell biology have estimated a significantly reduced risk of radiation-induced secondary malignancy with PRT. Clinical data are emerging supporting the lower incidence of secondary malignancies after PRT compared with historical photon data, though longer follow-up in proton treated cohorts is awaited. This article reviews the current dosimetric and clinical literature evaluating the incidence of and risk factors associated with radiation-induced secondary malignancy following PRT.
Collapse
Affiliation(s)
- Bree R Eaton
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA
| | - Shannon M MacDonald
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA
| | - Torunn I Yock
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA
| | - Nancy J Tarbell
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA
| |
Collapse
|
152
|
Laprie A, Hu Y, Alapetite C, Carrie C, Habrand JL, Bolle S, Bondiau PY, Ducassou A, Huchet A, Bertozzi AI, Perel Y, Moyal É, Balosso J. Paediatric brain tumours: A review of radiotherapy, state of the art and challenges for the future regarding protontherapy and carbontherapy. Cancer Radiother 2015; 19:775-89. [PMID: 26548600 DOI: 10.1016/j.canrad.2015.05.028] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 05/18/2015] [Accepted: 05/21/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE Brain tumours are the most frequent solid tumours in children and the most frequent radiotherapy indications in paediatrics, with frequent late effects: cognitive, osseous, visual, auditory and hormonal. A better protection of healthy tissues by improved beam ballistics, with particle therapy, is expected to decrease significantly late effects without decreasing local control and survival. This article reviews the scientific literature to advocate indications of protontherapy and carbon ion therapy for childhood central nervous system cancer, and estimate the expected therapeutic benefits. MATERIALS AND METHODS A systematic review was performed on paediatric brain tumour treatments using Medline (from 1966 to March of 2014). To be included, clinical trials had to meet the following criteria: age of patients 18 years or younger, treated with radiation, and report of survival. Studies were also selected according to the evidence level. A secondary search of cited references found other studies about cognitive functions, quality of life, the comparison of photon and proton dosimetry showing potential dose escalation and/or sparing of organs at risk with protontherapy; and studies on dosimetric and technical issues related to protontherapy. RESULTS A total of 7051 primary references published were retrieved, among which 40 clinical studies and 60 papers about quality of life, dose distribution and dosimetry were analysed, as well as the ongoing clinical trials. These papers have been summarized and reported in a specific document made available to the participants of a final 1-day workshop. Tumours of the meningeal envelop and bony cranial structures were excluded from the analysis. Protontherapy allows outstanding ballistics to target the tumour area, while substantially decreasing radiation dose to the normal tissues. There are many indications of protontherapy for paediatric brain tumours in curative intent, either for localized treatment of ependymomas, germ-cell tumours, craniopharyngiomas, low-grade gliomas; or panventricular irradiation of pure non-secreting germinoma; or craniospinal irradiation of medulloblastomas and metastatic pure germinomas. Carbon ion therapy is just emerging and may be studied for highly aggressive and radioresistant tumours, as an initial treatment for diffuse brainstem gliomas, and for relapse of high-grade gliomas. CONCLUSION Both protontherapy and carbon ion therapy are promising for paediatric brain tumours. The benefit of decreasing late effects without altering survival has been described for most paediatric brain tumours with protontherapy and is currently assessed in ongoing clinical trials with up-to-date proton devices. Unfortunately, in 2015, only a minority of paediatric patients in France can receive protontherapy due to the lack of equipment.
Collapse
Affiliation(s)
- A Laprie
- Université Paul-Sabatier, Toulouse, France; Institut Claudius-Regaud, institut universitaire du cancer de Toulouse (IUCT)-Oncopole, radiation oncology, 1, avenue Irene-Joliot-Curie, 31059 Toulouse, France; Périclès-France-Hadron, Toulouse, France.
| | - Y Hu
- GCS-Étoile-France-Hadron, Lyon, France
| | - C Alapetite
- Institut Curie Paris Orsay (ICPO)-France-Hadron, Orsay, France
| | - C Carrie
- GCS-Étoile-France-Hadron, Lyon, France; Centre Léon-Bérard, Lyon, France
| | - J-L Habrand
- Institut Curie Paris Orsay (ICPO)-France-Hadron, Orsay, France; Université Paris Sud, Orsay, France; Archade-France-Hadron, Caen, France; Centre François-Baclesse, Caen, France; Gustave-Roussy, Villejuif, France
| | - S Bolle
- Institut Curie Paris Orsay (ICPO)-France-Hadron, Orsay, France; Impact-France-Hadron, Nice, France
| | - P-Y Bondiau
- Centre Antoine-Lacassagne, Nice, France; CHU de Bordeaux, Bordeaux, France
| | - A Ducassou
- Institut Claudius-Regaud, institut universitaire du cancer de Toulouse (IUCT)-Oncopole, radiation oncology, 1, avenue Irene-Joliot-Curie, 31059 Toulouse, France; Périclès-France-Hadron, Toulouse, France
| | - A Huchet
- Hôpital des Enfants, Toulouse, France
| | - A-I Bertozzi
- Périclès-France-Hadron, Toulouse, France; Université Grenoble Alpes, Grenoble, France
| | - Y Perel
- Université Grenoble Alpes, Grenoble, France
| | - É Moyal
- Université Paul-Sabatier, Toulouse, France; Institut Claudius-Regaud, institut universitaire du cancer de Toulouse (IUCT)-Oncopole, radiation oncology, 1, avenue Irene-Joliot-Curie, 31059 Toulouse, France; Périclès-France-Hadron, Toulouse, France
| | - J Balosso
- GCS-Étoile-France-Hadron, Lyon, France; CHU de Grenoble, Grenoble, France
| |
Collapse
|
153
|
Wang D. A critical appraisal of the clinical utility of proton therapy in oncology. MEDICAL DEVICES-EVIDENCE AND RESEARCH 2015; 8:439-46. [PMID: 26604838 PMCID: PMC4630192 DOI: 10.2147/mder.s65594] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Proton therapy is an emerging technology for providing radiation therapy to cancer patients. The depth dose distribution of a proton beam makes it a preferable radiation modality as it reduces radiation to the healthy tissue outside the tumor, compared with conventional photon therapy. While theoretically beneficial, its clinical values are still being demonstrated from the increasing number of patients treated with proton therapy, from several dozen proton therapy centers around the world. High equipment and facility costs are often the major obstacle for its wider adoption. Because of the high cost and lack of definite clinical evidence of its superiority, proton therapy treatment faces criticism on its cost-effectiveness. Technological development is causing a gradual lowering of costs, and research and clinical studies are providing further evidence on its clinical utility.
Collapse
Affiliation(s)
- Dongxu Wang
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| |
Collapse
|
154
|
Schneider U, Hälg R. The Impact of Neutrons in Clinical Proton Therapy. Front Oncol 2015; 5:235. [PMID: 26557501 PMCID: PMC4617104 DOI: 10.3389/fonc.2015.00235] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Accepted: 10/06/2015] [Indexed: 11/13/2022] Open
Abstract
In proton therapy, high-energy proton beams cause the production of secondary neutrons. This leads to an unwanted dose contribution, which can be considerable for tissues outside of the target volume regarding the long-term health of cancer patients. Due to the high biological effectiveness of neutrons with regard to cancer induction, small neutron doses can be important. Published comparisons of neutron dose measurements and the corresponding estimates of cancer risk between different treatment modalities differ over orders of magnitude. In this report, the controversy about the impact of the neutron dose in proton therapy is critically discussed and viewed in the light of new epidemiological studies. In summary, the impact of neutron dose on cancer risk can be determined correctly only if the dose distributions are carefully measured or computed. It is important to include not only the neutron component into comparisons but also the complete deposition of energy as precisely as possible. Cancer risk comparisons between different radiation qualities, treatment machines, and techniques have to be performed under similar conditions. It seems that in the past, the uncertainty in the models which lead from dose to risk were overestimated when compared with erroneous dose comparisons. Current risk models used with carefully obtained dose distributions predict a second cancer risk reduction for active protons vs. photons and a more or less constant risk of passive protons vs. photons. Those findings are in general agreement with newly obtained epidemiologically results.
Collapse
Affiliation(s)
- Uwe Schneider
- Institute of Physics, Science Faculty, University of Zürich, Zürich, Switzerland
- Radiotherapy Hirslanden, Zürich, Switzerland
| | - Roger Hälg
- Institute of Physics, Science Faculty, University of Zürich, Zürich, Switzerland
- Radiotherapy Hirslanden, Zürich, Switzerland
| |
Collapse
|
155
|
Gurtner K, Baumann M. [Proton therapy of pediatric rhabdomyosarcoma: Same tumor control as photon therapy, with less adverse effects]. Strahlenther Onkol 2015; 191:814-6. [PMID: 26385859 DOI: 10.1007/s00066-015-0878-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Kristin Gurtner
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.
| | - Michael Baumann
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland
| |
Collapse
|
156
|
Dwyer M. Defining the role of proton therapy in the optimal management of paediatric patients in Australia and New Zealand. J Med Imaging Radiat Oncol 2015; 60:105-11. [DOI: 10.1111/1754-9485.12391] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 08/16/2015] [Indexed: 02/01/2023]
Affiliation(s)
- Mary Dwyer
- Department of Radiation Oncology and Cancer Imaging; Peter MacCallum Cancer Centre; Melbourne Victoria Australia
| |
Collapse
|
157
|
Girdhani S, Sachs R, Hlatky L. Biological effects of proton radiation: an update. RADIATION PROTECTION DOSIMETRY 2015; 166:334-338. [PMID: 25897135 DOI: 10.1093/rpd/ncv178] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Proton radiation provides significant dosimetric advantages when compared with gamma radiation due to its superior energy deposition characteristics. Although the physical aspects of proton radiobiology are well understood, biological and clinical endpoints are understudied. The current practice to assume the relative biological effectiveness of low linear energy transfer (LET) protons to be a generic value of about 1.1 relative to photons likely obscures important unrecognised differentials in biological response between these radiation qualities. A deeper understanding of the biological properties induced by proton radiation would have both radiobiological and clinical impact. This article briefly points to some of the literature pertinent to the effects of protons on tissue-level processes that modify disease progression, such as angiogenesis, cell invasion and cancer metastasis. Recent findings hint that proton radiation may, in addition to offering improved radio-therapeutic targeting, be a means to provide a new dimension for increasing therapeutic benefits for patients by manipulating these tissue-level processes.
Collapse
Affiliation(s)
- S Girdhani
- Center of Cancer Systems Biology, GRI, Tufts University School of Medicine, Boston, MA, USA
| | - R Sachs
- Center of Cancer Systems Biology, GRI, Tufts University School of Medicine, Boston, MA, USA Department of Mathematics, University of California, Berkeley, CA, USA
| | - L Hlatky
- Center of Cancer Systems Biology, GRI, Tufts University School of Medicine, Boston, MA, USA
| |
Collapse
|
158
|
Keole SR. Proton therapy for esthesioneuroblastoma: Can we shed some light on a murky topic? Pediatr Blood Cancer 2015; 62:1514-5. [PMID: 25940447 DOI: 10.1002/pbc.25578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Accepted: 04/07/2015] [Indexed: 11/12/2022]
Affiliation(s)
- Sameer R Keole
- Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona
| |
Collapse
|
159
|
Lucas JT, Ladra MM, MacDonald SM, Busse PM, Friedmann AM, Ebb DH, Marcus KJ, Tarbell NJ, Yock TI. Proton therapy for pediatric and adolescent esthesioneuroblastoma. Pediatr Blood Cancer 2015; 62:1523-8. [PMID: 25820437 PMCID: PMC9124545 DOI: 10.1002/pbc.25494] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 01/19/2015] [Indexed: 11/07/2022]
Abstract
BACKGROUND Esthesioneuroblastoma (EN) of the paranasal sinus comprises less than 3% of tumors of in pediatric and adolescent patients [1]. The collective adult literature indicates a critical role for radiotherapy in attaining cure [2], yet pediatric outcome data is limited. Radiation in pediatric patients with EN can cause significant morbidity due to the proximity of critical structures. Proton radiotherapy offers a potential dosimetric benefit that may improve long-term survival and toxicity outcomes in the pediatric population [3]. METHODS We retrospectively identified eight patients treated for EN with proton radiotherapy from 2000-2013. Times to event clinical endpoints are summarized using the Kaplan-Meier methods and are from the date of radiotherapy completion. Toxicities are reviewed and graded according to CTCAE v. 4.0. RESULTS Median follow up was 4.6 years for survivors (range 0.8-9.4 years). The 4 year overall survival was 87.5%. Four of eight patients (one elective) had comprehensive neck radiotherapy. No local or regional failures were observed. Two patients failed distantly with diffuse leptomeningeal disease and intraparenchymal brain metastases, at 0.6 and 1.3 months respectively. Four patients developed radiation related late toxicities including endocrine dysfunction, two cases of grade 2 retinopathy and one case of grade 3 optic neuropathy. CONCLUSIONS In a limited cohort, proton radiotherapy appears to provide excellent locoregional disease control even in those patients with locally advanced disease and intracranial extension. Distant failure determined overall survival in our cohort. Toxicities were acceptable given disease location and extent.
Collapse
Affiliation(s)
- John T. Lucas
- Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | | | | | - Paul M. Busse
- Department of Radiation Oncology, Boston, Massachusetts
| | | | - David H. Ebb
- Pediatrics at Massachusetts General Hospital, Boston, Massachusetts
| | - Karen J. Marcus
- Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts
| | | | - Torunn I Yock
- Department of Radiation Oncology, Boston, Massachusetts,Corresponding author: Torunn I. Yock, MD MCH, Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Proton Center, Room 110, Boston, MA 02114, PH: 617 726-6876, FAX: 617-724-9532,
| |
Collapse
|
160
|
Weber DC, Badiyan S, Malyapa R, Albertini F, Bolsi A, Lomax AJ, Schneider R. Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute. Neuro Oncol 2015; 18:236-43. [PMID: 26323608 DOI: 10.1093/neuonc/nov154] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 07/13/2015] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Skull-base chondrosarcoma (ChSa) is a rare disease, and the prognostication of this disease entity is ill defined. METHODS We assessed the long-term local control (LC) results, overall survival (OS), and prognostic factors of skull-base ChSa patients treated with pencil beam scanning proton therapy (PBS PT). Seventy-seven (male, 35; 46%) patients with histologically confirmed ChSa were treated at the Paul Scherrer Institute. Median age was 38.9 years (range, 10.2-70.0y). Median delivered dose was 70.0 GyRBE (range, 64.0-76.0 GyRBE). LC, OS, and toxicity-free survival (TFS) rates were calculated using the Kaplan Meier method. RESULTS After a mean follow-up of 69.2 months (range, 4.6-190.8 mo), 6 local (7.8%) failures were observed, 2 of which were late failures. Five (6.5%) patients died. The actuarial 8-year LC and OS were 89.7% and 93.5%, respectively. Tumor volume > 25 cm(3) (P = .02), brainstem/optic apparatus compression at the time of PT (P = .04) and age >30 years (P = .08) were associated with lower rates of LC. High-grade (≥3) radiation-induced toxicity was observed in 6 (7.8%) patients. The 8-year high-grade TFS was 90.8%. A higher rate of high-grade toxicity was observed for older patients (P = .073), those with larger tumor volume (P = .069), and those treated with 5 weekly fractions (P = .069). CONCLUSIONS This is the largest PT series reporting the outcome of patients with low-grade ChSa of the skull base treated with PBS only. Our data indicate that protons are both safe and effective. Tumor volume, brainstem/optic apparatus compression, and age were prognosticators of local failures.
Collapse
Affiliation(s)
- Damien C Weber
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| | - Shahed Badiyan
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| | - Robert Malyapa
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| | - Francesca Albertini
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| | - Alessandra Bolsi
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| | - Antony J Lomax
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| | - Ralf Schneider
- Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.)
| |
Collapse
|
161
|
McGee KP, Hu Y, Tryggestad E, Brinkmann D, Witte B, Welker K, Panda A, Haddock M, Bernstein MA. MRI in radiation oncology: Underserved needs. Magn Reson Med 2015; 75:11-4. [PMID: 26173404 DOI: 10.1002/mrm.25826] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Accepted: 06/09/2015] [Indexed: 12/12/2022]
Affiliation(s)
- Kiaran P McGee
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Yanle Hu
- Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona, USA
| | - Erik Tryggestad
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Debra Brinkmann
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Bob Witte
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Kirk Welker
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Anshuman Panda
- Department of Radiology, Mayo Clinic, Scottsdale, Arizona, USA
| | - Michael Haddock
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | | |
Collapse
|
162
|
Abstract
Sarcomas are a heterogeneous group of tumors that can occur in a wide array of anatomic sites and age ranges with varying histologies. Proton beam therapy, as compared with advanced x-ray radiation therapy techniques, can substantially lower dose to nontarget tissues. This dosimetric advantage can potentially allow for improvement of the therapeutic ratio in the treatment of many of the sarcomas by either increasing the local control, via increased dose to the target, or by decreasing the normal tissue complications, via lowered dose to the avoidance structures. This article reviews the key dosimetric studies and clinical outcomes published to date documenting the potential role proton beam therapy may play in the treatment of sarcomas.
Collapse
|
163
|
Abstract
Embryonal brain tumors are a heterogeneous group of neoplasms that primarily occur in infants and young children. They are highly cellular tumors with brisk mitotic activity, and they share a propensity for dissemination throughout the neuroaxis. Emerging molecular data enable improved diagnostic and prognostic discrimination for these tumors. Because of their aggressive potential, they are treated similarly with multimodality therapy including maximal safe resection, chemotherapy, and age- and risk-adapted radiotherapy. Craniospinal irradiation is commonly used in the treatment of these patients, especially in those older than 3 years. Because proton therapy allows for increased sparing of the anterior structures in craniospinal irradiation, there is a particular interest in using proton therapy to treat these young patients. For very young patients treated with focal fields only, proton therapy also decreases unnecessary radiation exposure to uninvolved intracranial structures. It is hoped that the use of proton therapy for these vulnerable patients will translate into decreased long-term neurocognitive, endocrine, vascular, and developmental effects, in addition to a decreased risk of second malignancies. This review describes the role of radiation in general and proton therapy in particular for the treatment of medulloblastoma, central nervous system primitive neuroectodermal tumors, atypical teratoid/rhabdoid tumors, and the recently described embryonal tumor with multilayered rosettes.
Collapse
|
164
|
Abstract
Hodgkin lymphoma and non-Hodgkin lymphoma are common hematologic malignancies with such a favorable prognosis that many survivors live decades after combined chemotherapy and radiotherapy. These survivors, however, are at risk of developing late treatment adverse effects from collateral damage, including secondary malignancies, cardiac toxicities, and ischemic heart diseases. Recent efforts have successfully reduced the radiation dose and treatment field without compromising cure rates. Proton therapy has the potential of further lowering the treatment-related toxicity owing to its ability to deposit a high dose only at the target. Although this finding has been supported by several current dosimetric studies, its utilization in the management of lymphoma has been limited during the past 5 years because of the paucity of facilities and the difficulty of obtaining insurance coverage. With diligent follow-up, the clinical impact of proton therapy will be established to improve the therapeutic ratio and to reduce late treatment-related morbidity.
Collapse
|
165
|
Abstract
Through unique physical dose deposition properties, proton beam therapy (PBT) potentiates radiation dose escalation to target tissue while minimizing radiation exposure to nontarget organs. Proton beam therapy has been used to treat prostate cancer for several decades; however, access to proton centers has been restricted to the limited number of proton centers. Because of recent enhancements in availability and treatment delivery systems, interest in PBT has been burgeoning among oncologists, industry experts, and prostate cancer patients. As a result, the importance of understanding the collective experience to date and technical aspects of PBT delivery has become increasingly important in cancer medicine. This review article is intended to discuss the fundamentals of PBT treatment, critically review the literature on PBT for localized prostate cancer, and describe the continued development of proton beam technology for the treatment of prostate cancer.
Collapse
Affiliation(s)
- Thomas J Pugh
- From the Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
166
|
Abstract
Radiation therapy (RT) plays a critical role in the local tumor control of benign and low-grade central nervous system tumors in children but is not without the risk of long-term treatment-related sequelae. Proton therapy (PRT) is an advanced RT modality with a unique dose-deposition pattern that allows for treatment of a target volume with reduced scatter dose delivered to normal tissues compared with conventional photon RT and is now increasingly utilized in children with the hope of mitigating radiation-induced late effects. This article reviews the current literature evaluating the use of PRT in benign and low-grade pediatric central nervous system tumors such as low-grade glioma, craniopharyngioma, and ependymoma. Multiple dosimetric studies support the use of PRT by demonstrating the ability of PRT to better spare critical structures important for cognitive development, endocrine function, and hearing preservation and to reduce the total body dose associated with second malignancy risk. Early clinical data demonstrate that PRT is well tolerated with rates of local tumor control comparable to conventional photon RT series, and long-term clinical data are awaited.
Collapse
|
167
|
Rieber JG, Kessel KA, Witt O, Behnisch W, Kulozik AE, Debus J, Combs SE. Treatment tolerance of particle therapy in pediatric patients. Acta Oncol 2015; 54:1049-55. [PMID: 25615893 DOI: 10.3109/0284186x.2014.998273] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
UNLABELLED Curative treatment of pediatric cancer not only focuses on long-term survival, but also on reducing treatment-related side effects. Advantages of particle therapy are mainly due to their physical ability of significantly reducing integral dose. METHODS Between January 2009 and December 2012, we treated 83 pediatric patients (aged 21 and younger) at the Heidelberg Ion Therapy Center at University Hospital of Heidelberg (HIT). In total 56 patients (67%) received proton irradiation, while 25 (30%) patients were treated with carbon ions (C12). Two patients received both treatments (3%). Treatment toxicity was analyzed retrospectively and documented according to the CTCAE/RTOG classification. In a second step, treatment toxicity from ion therapy was analyzed in comparison to treatment toxicity during photon irradiation of a comparable historical group of 19 pediatric patients. RESULTS In all patients, particle therapy was tolerated well (median follow-up time 3.7 months), children (20 patients) with at least two follow-up visits showed a median follow-up time of 10.2 months. During the first two months patients mainly suffered from radiogenic skin reaction (63%), mucositis (30%), headache and dizziness (35%) as well as nausea and vomiting (13%). Severe toxicity reaction (grade II-IV) was only seen in patients who had intensive simultaneous chemotherapy or who had undergone several operations in the irradiated area before radiotherapy (18%). Treatment toxicity during ion therapy was comparable to treatment toxicity from photon irradiation of a historical group. CONCLUSIONS In comparison to conventional therapy, patients with particle therapy do not suffer from increased acute treatment-related toxicity during the first months. More experience with particle therapy will be needed during the next years to help to thoroughly evaluate the high potential of ion therapy.
Collapse
Affiliation(s)
- Juliane G. Rieber
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Heidelberg Institute of Radiation Oncology, Germany
| | - Kerstin A. Kessel
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Heidelberg Institute of Radiation Oncology, Germany
| | - Olaf Witt
- CCU Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany
| | - Wolfgang Behnisch
- Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany
| | - Andreas E. Kulozik
- Department of Pediatric Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany
| | - Jürgen Debus
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Heidelberg Institute of Radiation Oncology, Germany
| | - Stephanie E. Combs
- Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- Department of Radiation Oncology, Klinikum Rechts der Isar, Technische Universität München (TUM), Munich, Germany
- Heidelberg Institute of Radiation Oncology, Germany
| |
Collapse
|
168
|
Barcellos-Hoff MH, Blakely EA, Burma S, Fornace AJ, Gerson S, Hlatky L, Kirsch DG, Luderer U, Shay J, Wang Y, Weil MM. Concepts and challenges in cancer risk prediction for the space radiation environment. LIFE SCIENCES IN SPACE RESEARCH 2015; 6:92-103. [PMID: 26256633 DOI: 10.1016/j.lssr.2015.07.006] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2015] [Revised: 07/08/2015] [Accepted: 07/09/2015] [Indexed: 06/04/2023]
Abstract
Cancer is an important long-term risk for astronauts exposed to protons and high-energy charged particles during travel and residence on asteroids, the moon, and other planets. NASA's Biomedical Critical Path Roadmap defines the carcinogenic risks of radiation exposure as one of four type I risks. A type I risk represents a demonstrated, serious problem with no countermeasure concepts, and may be a potential "show-stopper" for long duration spaceflight. Estimating the carcinogenic risks for humans who will be exposed to heavy ions during deep space exploration has very large uncertainties at present. There are no human data that address risk from extended exposure to complex radiation fields. The overarching goal in this area to improve risk modeling is to provide biological insight and mechanistic analysis of radiation quality effects on carcinogenesis. Understanding mechanisms will provide routes to modeling and predicting risk and designing countermeasures. This white paper reviews broad issues related to experimental models and concepts in space radiation carcinogenesis as well as the current state of the field to place into context recent findings and concepts derived from the NASA Space Radiation Program.
Collapse
Affiliation(s)
| | | | - Sandeep Burma
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | | | | | - Lynn Hlatky
- Center of Cancer Systems Biology, Tufts University, Boston, MA, USA
| | | | | | - Jerry Shay
- University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Ya Wang
- Emory University, Atlanta, GA, USA
| | | |
Collapse
|
169
|
Abstract
Hodgkin lymphoma has gone from an incurable disease to one for which the majority of patients will be cured. Combined chemotherapy and radiotherapy achieves the best disease control rates and results in many long-term survivors. As a result, a majority of long-term Hodgkin lymphoma survivors live to experience severe late treatment-related complications, especially cardiovascular disease and second malignancies. The focus of research and treatment for Hodgkin lymphoma is to maintain the current high rates of disease control while reducing treatment-related morbidity and mortality. Efforts to reduce late treatment complications focus on improvements in both systemic therapies and radiotherapy. Herein we review the basis for the benefits of proton therapy over conventional X-ray therapy. We review outcomes of Hodgkin lymphoma treated with proton therapy, and discuss the ability of protons to reduce radiation dose to organs at risk and the impact on the most significant late complications related to the treatment.
Collapse
|
170
|
Patel S, Drodge S, Jacques A, Warkentin H, Powell K, Chafe S. A Comparative Planning Analysis and Integral Dose of Volumetric Modulated Arc Therapy, Helical Tomotherapy, and Three-dimensional Conformal Craniospinal Irradiation for Pediatric Medulloblastoma. J Med Imaging Radiat Sci 2015; 46:134-140. [PMID: 31052086 DOI: 10.1016/j.jmir.2014.11.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2014] [Revised: 11/04/2014] [Accepted: 11/20/2014] [Indexed: 12/19/2022]
Abstract
INTRODUCTION The purpose of this study was to compare volumetric modulated arc therapy (VMAT) with helical tomotherapy (HT) and three-dimensional conformal radiation therapy (3D-CRT) for craniospinal irradiation (CSI) in children with medulloblastoma. METHODS Five children treated with 3D-CRT were retrospectively replanned with HT and VMAT. Tomotherapy plans used a single helical arc, thereby eliminating field junctions. VMAT plans used two arcs rotating alternatively clockwise and counterclockwise, respectively. Conformity and homogeneity indices, dose-volume histograms, integral doses, monitor units delivered, and beam-on times were compared. RESULTS VMAT showed an improved mean conformity index of 1.05 in comparison with 3D-CRT (1.58, P = .04) and HT (1.34, P = .04). The mean homogeneity index of VMAT (1.13) was not significantly different from 3D-CRT (1.16) but higher than HT (1.08, P = .04). For normal tissues, VMAT resulted in a lower mean dose to the skin, eyes, lenses, optic nerves, cochlea, esophagus, heart, peritoneal cavity, bladder, and rectum compared with 3D-CRT (all P = .04). There were few significant differences in dose-volume statistics for normal tissues between VMAT and HT. The mean nontarget tissue integral dose for VMAT of 80.8 J was significantly lower than for 3D-CRT (91.5 J, P = .04) and HT (95.6 J, P = .04). Body and nontarget tissue integral doses were lowest with VMAT in every patient. CONCLUSIONS For CSI, VMAT provides comparable normal tissue sparing with tomotherapy and may reduce the integral dose. Compared with 3D-CRT, VMAT improved normal tissue sparing at higher doses despite larger volumes receiving lower doses. These findings have potential implications in the risk of the development of late adverse effects and radiation-related second malignancies in children with curable primary disease.
Collapse
Affiliation(s)
- Samir Patel
- Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Canada.
| | - Suzanne Drodge
- Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Canada
| | - Amanda Jacques
- Department of Medical Physics, Cross Cancer Institute, Edmonton, Canada
| | - Heather Warkentin
- Department of Medical Physics, Cross Cancer Institute, Edmonton, Canada
| | - Kent Powell
- Department of Medical Physics, Cross Cancer Institute, Edmonton, Canada
| | - Susan Chafe
- Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Canada
| |
Collapse
|
171
|
Scaringi C, Minniti G, Bozzao A, Giangaspero F, Falco T, Greco A, De Sanctis V, Romano A, Enrici RM. Radiation-induced malignant meningioma following proton beam therapy for a choroidal melanoma. J Clin Neurosci 2015; 22:1036-7. [DOI: 10.1016/j.jocn.2014.12.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 12/18/2014] [Accepted: 12/20/2014] [Indexed: 02/07/2023]
|
172
|
Sachsman S, Flampouri S, Li Z, Lynch J, Mendenhall NP, Hoppe BS. Proton therapy in the management of non-Hodgkin lymphoma. Leuk Lymphoma 2015; 56:2608-12. [PMID: 25669925 PMCID: PMC4732409 DOI: 10.3109/10428194.2015.1014364] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Proton therapy (PT) is a highly conformal type of radiation therapy that can target the tumor while sparing dose to surrounding normal tissues. This study reviews a single institution's experience managing patients with non-Hodgkin lymphoma (NHL) treated with PT. Eleven patients with NHL were treated with PT from January 2008 to January 2014 on an institutional review board-approved outcomes tracking protocol, and included patients with indolent orbital lymphoma (n = 4), primary mediastinal B-cell lymphoma (n = 3), plasmablastic lymphoma (n = 2) and natural killer (NK) T-cell lymphoma (n = 2). The median follow-up was 38 months. The 2-year rate of local control was 91%, with one patient with NK T-cell lymphoma having recurrence in-field. Toxicities were limited to grade 2 at highest, during follow-up. PT is a feasible and effective treatment for NHL. Early outcomes are favorable. Longer follow-up and more patients are needed to confirm our findings.
Collapse
Affiliation(s)
- Suzanne Sachsman
- a University of Florida Proton Therapy Institute , Jacksonville , FL , USA
| | - Stella Flampouri
- a University of Florida Proton Therapy Institute , Jacksonville , FL , USA
| | - Zuofeng Li
- a University of Florida Proton Therapy Institute , Jacksonville , FL , USA
| | - James Lynch
- b Department of Hematology and Oncology , University of Florida, College of Medicine , Gainesville , FL , USA
| | - Nancy P Mendenhall
- a University of Florida Proton Therapy Institute , Jacksonville , FL , USA
| | - Bradford S Hoppe
- a University of Florida Proton Therapy Institute , Jacksonville , FL , USA
| |
Collapse
|
173
|
Radiation for Prostate Cancer: Intensity Modulated Radiation Therapy versus Proton Beam. J Urol 2015; 193:1089-91. [DOI: 10.1016/j.juro.2015.01.069] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/12/2015] [Indexed: 11/17/2022]
|
174
|
Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, Vatnitsky S, Chu WT. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol 2015; 16:e93-e100. [PMID: 25638685 DOI: 10.1016/s1470-2045(14)70412-7] [Citation(s) in RCA: 350] [Impact Index Per Article: 38.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Charged particle therapy is generally regarded as cutting-edge technology in oncology. Many proton therapy centres are active in the USA, Europe, and Asia, but only a few centres use heavy ions, even though these ions are much more effective than x-rays owing to the special radiobiological properties of densely ionising radiation. The National Institute of Radiological Sciences (NIRS) Chiba, Japan, has been treating cancer with high-energy carbon ions since 1994. So far, more than 8000 patients have had this treatment at NIRS, and the centre thus has by far the greatest experience in carbon ion treatment worldwide. A panel of radiation oncologists, radiobiologists, and medical physicists from the USA and Europe recently completed peer review of the carbon ion therapy at NIRS. The review panel had access to the latest developments in treatment planning and beam delivery and to all updated clinical data produced at NIRS. A detailed comparison with the most advanced results obtained with x-rays or protons in Europe and the USA was then possible. In addition to those tumours for which carbon ions are known to produce excellent results, such as bone and soft-tissue sarcoma of the skull base, head and neck, and pelvis, promising data were obtained for other tumours, such as locally recurrent rectal cancer and pancreatic cancer. The most serious impediment to the worldwide spread of heavy ion therapy centres is the high initial capital cost. The 20 years of clinical experience at NIRS can help guide strategic decisions on the design and construction of new heavy ion therapy centres.
Collapse
Affiliation(s)
- Tadashi Kamada
- National Institute of Radiological Sciences, Chiba, Japan
| | | | | | - Jürgen Debus
- University of Heidelberg and Heidelberg Ion Therapy Centre, Heidelberg, Germany
| | | | - Marco Durante
- GSI Helmholtz Center for Heavy Ion Research and Darmstadt University of Technology, Darmstadt, Germany.
| | - Oliver Jäkel
- University of Heidelberg and Heidelberg Ion Therapy Centre, Heidelberg, Germany
| | | | - Roberto Orecchia
- CNAO Foundation, Pavia, and European Institute of Oncology, Milan, Italy
| | | | | | - William T Chu
- Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| |
Collapse
|
175
|
Cuaron JJ, Chon B, Tsai H, Goenka A, DeBlois D, Ho A, Powell S, Hug E, Cahlon O. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys 2015; 92:284-91. [PMID: 25754632 DOI: 10.1016/j.ijrobp.2015.01.005] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Revised: 12/02/2014] [Accepted: 01/07/2015] [Indexed: 11/30/2022]
Abstract
PURPOSE To report dosimetry and early toxicity data in breast cancer patients treated with postoperative proton radiation therapy. METHODS AND MATERIALS From March 2013 to April 2014, 30 patients with nonmetastatic breast cancer and no history of prior radiation were treated with proton therapy at a single proton center. Patient characteristics and dosimetry were obtained through chart review. Patients were seen weekly while on treatment, at 1 month after radiation therapy completion, and at 3- to 6-month intervals thereafter. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. Frequencies of toxicities were tabulated. RESULTS Median dose delivered was 50.4 Gy (relative biological equivalent [RBE]) in 5 weeks. Target volumes included the breast/chest wall and regional lymph nodes including the internal mammary lymph nodes (in 93%). No patients required a treatment break. Among patients with >3 months of follow-up (n=28), grade 2 dermatitis occurred in 20 patients (71.4%), with 8 (28.6%) experiencing moist desquamation. Grade 2 esophagitis occurred in 8 patients (28.6%). Grade 3 reconstructive complications occurred in 1 patient. The median planning target volume V95 was 96.43% (range, 79.39%-99.60%). The median mean heart dose was 0.88 Gy (RBE) [range, 0.01-3.20 Gy (RBE)] for all patients, and 1.00 Gy (RBE) among patients with left-sided tumors. The median V20 of the ipsilateral lung was 16.50% (range, 6.1%-30.3%). The median contralateral lung V5 was 0.34% (range, 0%-5.30%). The median maximal point dose to the esophagus was 45.65 Gy (RBE) [range, 0-65.4 Gy (RBE)]. The median contralateral breast mean dose was 0.29 Gy (RBE) [range, 0.03-3.50 Gy (RBE)]. CONCLUSIONS Postoperative proton therapy is well tolerated, with acceptable rates of skin toxicity. Proton therapy favorably spares normal tissue without compromising target coverage. Further follow-up is necessary to assess for clinical outcomes and cardiopulmonary toxicities.
Collapse
Affiliation(s)
- John J Cuaron
- Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Brian Chon
- Procure Proton Therapy Center, Somerset, New Jersey
| | - Henry Tsai
- Procure Proton Therapy Center, Somerset, New Jersey
| | - Anuj Goenka
- Procure Proton Therapy Center, Somerset, New Jersey
| | | | - Alice Ho
- Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Simon Powell
- Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Eugen Hug
- Procure Proton Therapy Center, Somerset, New Jersey
| | - Oren Cahlon
- Memorial Sloan-Kettering Cancer Center, New York, New York; Procure Proton Therapy Center, Somerset, New Jersey.
| |
Collapse
|
176
|
Ioannides PJ, Hansen TM, McDonald MW. Proton and X-ray Radiation for Head and Neck Paragangliomas. Int J Part Ther 2015. [DOI: 10.14338/ijpt-14-00023.1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
177
|
Abstract
In addition to the physical advantages (Bragg peak), the use of charged particles in cancer therapy can be associated with distinct biological effects compared to X-rays. While heavy ions (densely ionizing radiation) are known to have an energy- and charge-dependent increased Relative Biological Effectiveness (RBE), protons should not be very different from sparsely ionizing photons. A slightly increased biological effectiveness is taken into account in proton treatment planning by assuming a fixed RBE of 1.1 for the whole radiation field. However, data emerging from recent studies suggest that, for several end points of clinical relevance, the biological response is differentially modulated by protons compared to photons. In parallel, research in the field of medical physics highlighted how variations in RBE that are currently neglected might actually result in deposition of significant doses in healthy organs. This seems to be relevant in particular for normal tissues in the entrance region and for organs at risk close behind the tumor. All these aspects will be considered and discussed in this review, highlighting how a re-discussion of the role of a variable RBE in proton therapy might be well-timed.
Collapse
|
178
|
Conroy R, Gomes L, Owen C, Buchsbaum J, Ahern V. Clinical equipoise: Protons and the child with craniopharyngioma. J Med Imaging Radiat Oncol 2014; 59:379-85. [DOI: 10.1111/1754-9485.12264] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Accepted: 10/08/2014] [Indexed: 11/28/2022]
Affiliation(s)
- Ruth Conroy
- Crown Princess Mary Cancer Centre; Westmead Hospital; Sydney New South Wales Australia
| | - Lavier Gomes
- Medical Imaging; Westmead Hospital; Sydney New South Wales Australia
| | - Catherine Owen
- Crown Princess Mary Cancer Centre; Westmead Hospital; Sydney New South Wales Australia
| | - Jeffrey Buchsbaum
- Departments of Radiation Oncology, Paediatrics, and Neurological Surgery; Indiana University College of Arts and Sciences; Indiana University School of Medicine; Bloomington Indiana USA
- Department of Physics; IU Proton Therapy Center; Riley Hospital for Children; Indiana University Hospital; Bloomington Indiana USA
| | - Verity Ahern
- Crown Princess Mary Cancer Centre; Westmead Hospital; Sydney New South Wales Australia
| |
Collapse
|
179
|
Marta GN, Murphy E, Chao S, Yu JS, Suh JH. The incidence of second brain tumors related to cranial irradiation. Expert Rev Anticancer Ther 2014; 15:295-304. [PMID: 25482749 DOI: 10.1586/14737140.2015.989839] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Secondary brain tumor (SBT) is a devastating complication of cranial irradiation (CI). We reviewed the literature to determine the incidence of SBT as related to specific radiation therapy (RT) treatment modalities. The relative risk of radiation-associated SBT after conventional and conformal RT is well established and ranges from 5.65 to 10.9; latent time to develop second tumor ranges from 5.8 to 22.4 years, depending on radiation dose and primary disease. Theories and dosimetric models suggest that intensity-modulated radiation therapy may result in an increased risk of SBT, but clinical evidence is limited. The incidence of stereotactic radiosurgery-related SBT is low. Initial data suggest that no increased risk from proton therapy and dosimetric models predict a lower incidence of SBT compared with photons. In conclusion, the incidence of SBT related to CI is low. Longer follow-up is needed to clarify the impact of intensity-modulated radiation therapy, proton therapy and other developing technologies.
Collapse
Affiliation(s)
- Gustavo Nader Marta
- Radiation Oncology Department, Hospital Sírio-Libanês, Rua Dona Adma Jafet 91., Sao Paulo, Sao Paulo 01308-050, Brazil
| | | | | | | | | |
Collapse
|
180
|
Plastaras JP, Berman AT, Freedman GM. Special Cases for Proton Beam Radiotherapy: Re-irradiation, Lymphoma, and Breast Cancer. Semin Oncol 2014; 41:807-19. [DOI: 10.1053/j.seminoncol.2014.10.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
181
|
Khan AJ, Goyal S, Vicini FA. Cardiac avoidance in breast radiotherapy: many choices for a worthwhile objective. Front Oncol 2014; 4:269. [PMID: 25340038 PMCID: PMC4187540 DOI: 10.3389/fonc.2014.00269] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Accepted: 09/14/2014] [Indexed: 11/13/2022] Open
Affiliation(s)
- Atif J Khan
- Rutgers Cancer Institute of New Jersey, Robert Wood Johnson University Hospital , New Brunswick, NJ , USA
| | - Sharad Goyal
- Rutgers Cancer Institute of New Jersey, Robert Wood Johnson University Hospital , New Brunswick, NJ , USA
| | - Frank A Vicini
- Michigan Healthcare Professionals , Farmington Hills, MI , USA
| |
Collapse
|
182
|
Ladra MM, Szymonifka JD, Mahajan A, Friedmann AM, Yong Yeap B, Goebel CP, MacDonald SM, Grosshans DR, Rodriguez-Galindo C, Marcus KJ, Tarbell NJ, Yock TI. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol 2014; 32:3762-70. [PMID: 25332253 DOI: 10.1200/jco.2014.56.1548] [Citation(s) in RCA: 95] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This prospective phase II study was designed to assess disease control and to describe acute and late adverse effects of treatment with proton radiotherapy in children with rhabdomyosarcoma (RMS). PATIENTS AND METHODS Fifty-seven patients with localized RMS (age 21 years or younger) or metastatic embryonal RMS (age 2 to 10 years) were enrolled between February 2005 and August 2012. All patients were treated with chemotherapy based on either vincristine, actinomycin, and cyclophosphamide or vincristine, actinomycin, and ifosfamide-based chemotherapy and proton radiation. Surgical resection was based on tumor site and accessibility. Common Terminology Criteria for Adverse Events, Version 3.0, was used to assess and grade adverse effects of treatment. Concurrent enrollment onto Children's Oncology Group or European Pediatric Sarcoma Study Group protocols was allowed. All pathology and imaging were reviewed at the treating institution. RESULTS Median follow-up was 47 months (range, 14 to 102 months) for survivors. Five-year event-free survival (EFS), overall survival (OS), and local control (LC) were 69%, 78%, and 81%, respectively, for the entire cohort. The 5-year LC by risk group was 93% for low-risk and 77% for intermediate-risk disease. There were 13 patients with grade 3 acute toxicity and three patients with grade 3 late toxicity. There were no acute or late toxicities higher than grade 3. CONCLUSION Five-year LC, EFS, and OS rates were similar to those observed in comparable trials that used photon radiation. Acute and late toxicity rates were favorable. Proton radiation appears to represent a safe and effective radiation modality for pediatric RMS.
Collapse
Affiliation(s)
- Matthew M Ladra
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jackie D Szymonifka
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Anita Mahajan
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Alison M Friedmann
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Beow Yong Yeap
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Claire P Goebel
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Shannon M MacDonald
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - David R Grosshans
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Carlos Rodriguez-Galindo
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Karen J Marcus
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Nancy J Tarbell
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Torunn I Yock
- Matthew M. Ladra, Jackie Szymonifka, Alison M. Friedmann, Beow Yong Yeap, Claire Goebel, Shannon M. MacDonald, Nancy J. Tarbell, Torunn I. Yock Massachusetts General Hospital, Harvard Medical School;, Carlos Rodriguez-Galindo, Karen J. Marcus, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Anita Mahajan and David Grosshans, The University of Texas MD Anderson Cancer Center, Houston, TX.
| |
Collapse
|
183
|
Ladra MM, Edgington SK, Mahajan A, Grosshans D, Szymonifka J, Khan F, Moteabbed M, Friedmann AM, MacDonald SM, Tarbell NJ, Yock TI. A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother Oncol 2014; 113:77-83. [PMID: 25443861 DOI: 10.1016/j.radonc.2014.08.033] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Revised: 08/10/2014] [Accepted: 08/12/2014] [Indexed: 10/24/2022]
Abstract
BACKGROUND Pediatric rhabdomyosarcoma (RMS) is highly curable, however, cure may come with significant radiation related toxicity in developing tissues. Proton therapy (PT) can spare excess dose to normal structures, potentially reducing the incidence of adverse effects. METHODS Between 2005 and 2012, 54 patients were enrolled on a prospective multi-institutional phase II trial using PT in pediatric RMS. As part of the protocol, intensity modulated radiation therapy (IMRT) plans were generated for comparison with clinical PT plans. RESULTS Target coverage was comparable between PT and IMRT plans with a mean CTV V95 of 100% for both modalities (p=0.82). However, mean integral dose was 1.8 times higher for IMRT (range 1.0-4.9). By site, mean integral dose for IMRT was 1.8 times higher for H&N (p<0.01) and GU (p=0.02), 2.0 times higher for trunk/extremity (p<0.01), and 3.5 times higher for orbit (p<0.01) compared to PT. Significant sparing was seen with PT in 26 of 30 critical structures assessed for orbital, head and neck, pelvic, and trunk/extremity patients. CONCLUSIONS Proton radiation lowers integral dose and improves normal tissue sparing when compared to IMRT for pediatric RMS. Correlation with clinical outcomes is necessary once mature long-term toxicity data are available.
Collapse
Affiliation(s)
- Matthew M Ladra
- Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | | | - Anita Mahajan
- The University of Texas MD Anderson Cancer Center, Houston, USA
| | - David Grosshans
- The University of Texas MD Anderson Cancer Center, Houston, USA
| | | | - Fazal Khan
- Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Maryam Moteabbed
- Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | | | | | - Nancy J Tarbell
- Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Torunn I Yock
- Massachusetts General Hospital, Harvard Medical School, Boston, USA.
| |
Collapse
|
184
|
Patel S, Kostaras X, Parliament M, Olivotto IA, Nordal R, Aronyk K, Hagen N. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? ACTA ACUST UNITED AC 2014; 21:251-62. [PMID: 25302033 DOI: 10.3747/co.21.2207] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Compared with photon therapy, proton-beam therapy (pbt) offers compelling advantages in physical dose distribution. Worldwide, gantry-based proton facilities are increasing in number, but no such facilities exist in Canada. To access pbt, Canadian patients must travel abroad for treatment at high cost. In the face of limited access, this report seeks to provide recommendations for the selection of patients most likely to benefit from pbt and suggests an out-of-country referral process. METHODS The medline, embase, PubMed, and Cochrane databases were systematically searched for studies published between January 1990 and May 2014 that evaluated clinical outcomes after pbt. A draft report developed through a review of evidence was externally reviewed and then approved by the Alberta Health Services Cancer Care Proton Therapy Guidelines steering committee. RESULTS Proton therapy is often used to treat tumours close to radiosensitive tissues and to treat children at risk of developing significant late effects of radiation therapy (rt). In uncontrolled and retrospective studies, local control rates with pbt appear similar to, or in some cases higher than, photon rt. Randomized trials comparing equivalent doses of pbt and photon rt are not available. SUMMARY Referral for pbt is recommended for patients who are being treated with curative intent and with an expectation for long-term survival, and who are able and willing to travel abroad to a proton facility. Commonly accepted indications for referral include chordoma and chondrosarcoma, intraocular melanoma, and solid tumours in children and adolescents who have the greatest risk for long-term sequelae. Current data do not provide sufficient evidence to recommend routine referral of patients with most head-and-neck, breast, lung, gastrointestinal tract, and pelvic cancers, including prostate cancer. It is recommended that all referrals be considered by a multidisciplinary team to select appropriate cases.
Collapse
Affiliation(s)
- S Patel
- Department of Radiation Oncology, Cross Cancer Institute, and Department of Oncology, University of Alberta, Edmonton, AB
| | - X Kostaras
- Guideline Utilization Resource Unit, Alberta Health Services, Calgary, AB
| | - M Parliament
- Department of Radiation Oncology, Cross Cancer Institute, and Department of Oncology, University of Alberta, Edmonton, AB
| | - I A Olivotto
- Division of Radiation Oncology, Tom Baker Cancer Centre, and University of Calgary, Calgary, AB
| | - R Nordal
- Division of Radiation Oncology, Tom Baker Cancer Centre, and University of Calgary, Calgary, AB
| | - K Aronyk
- Division of Neurosurgery, University of Alberta, Edmonton, AB
| | - N Hagen
- Guideline Utilization Resource Unit, Alberta Health Services, Calgary, AB
| |
Collapse
|
185
|
Dionisi F, Avery S, Lukens JN, Ding X, Kralik J, Kirk M, Roses RE, Amichetti M, Metz JM, Plastaras JP. Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report. Acta Oncol 2014; 53:1312-20. [PMID: 24797885 DOI: 10.3109/0284186x.2014.912351] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
BACKGROUND Adjuvant chemoradiotherapy improves both overall- and relapse-free survival in patients with resected gastric cancer. However, this comes at the cost of increased treatment-related toxicity. Proton therapy (PT) has distinct dosimetric characteristics that may reduce dose to normal tissues, improving the therapeutic ratio. The purpose of this treatment planning study is to compare PT and intensity-modulated x-ray therapy (IMXT) in gastric cancer with regards to normal tissue sparing. MATERIAL AND METHODS The patient population consisted of resected gastric cancer patients treated at a single institution between 2008 and 2013. Patients who had undergone 4D CT simulation were replanned to the originally delivered doses (45-54 Gy in 25-30 daily fractions) using six-field photon IMXT and 2-3-field PT (double scattering-uniform scanning techniques). RESULTS Thirteen patients were eligible for the planning comparison. IMXT provided slightly higher homogeneity indices (median values 0.04 ± 0.01 vs. 0.07 ± 0.01, p = 0.03). PT resulted in significantly (p < 0.05) lower intermediate-low doses for all the normal tissues examined (small bowel V15 82 ml vs. 133 ml, liver mean doses Gy 11.9 vs. 14.4 Gy, left/right kidney mean doses 5/0.9 Gy vs. 7.8/3.1 Gy, heart mean doses 7.4 Gy vs. 9.5 Gy). The total energy deposited outside the target volume was significantly lower with PT (median integral dose 90.1 J vs. 129 J). Four patients were treated with PT: treatment was feasible and verifications scans showed that target coverage was robust. CONCLUSION PT can contribute to normal tissue sparing in the adjuvant treatment of gastric cancer, with a potential benefit in terms of compliance to treatment, acute and late toxicities.
Collapse
Affiliation(s)
- Francesco Dionisi
- Proton Therapy Unit, Department of Oncology, Azienda Provinciale per i Servizi Sanitari (APSS) , Trento , Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
186
|
|
187
|
Rombi B, Timmermann B. Proton Beam Therapy for Pediatric Chordomas: State of the Art. Int J Part Ther 2014. [DOI: 10.14338/ijpt.13.00008.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
188
|
Abstract
Proton beam therapy, the most common form of heavy-particle radiation therapy, is not a new invention, but it has gained considerable public attention because of the high cost of installing and operating the rapidly increasing number of treatment centers. This article reviews the physical properties of proton beam therapy and focuses on the up-to-date clinical evidence comparing proton beam therapy with the more standard and widely available radiation therapy treatment alternatives. In a cost-conscious era of health care, the hypothetical benefits of proton beam therapy will have to be supported by demonstrable clinical gains. Proton beam therapy represents, through its scale and its cost, a battleground for the policy debate around managing expensive technology in modern medicine.
Collapse
Affiliation(s)
- Timur Mitin
- Timur Mitin, Massachusetts General Hospital, Boston, MA.
| | | |
Collapse
|
189
|
Abstract
Densely ionizing radiation has always been a main topic in radiobiology. In fact, α-particles and neutrons are sources of radiation exposure for the general population and workers in nuclear power plants. More recently, high-energy protons and heavy ions attracted a large interest for two applications: hadrontherapy in oncology and space radiation protection in manned space missions. For many years, studies concentrated on measurements of the relative biological effectiveness (RBE) of the energetic particles for different end points, especially cell killing (for radiotherapy) and carcinogenesis (for late effects). Although more recently, it has been shown that densely ionizing radiation elicits signalling pathways quite distinct from those involved in the cell and tissue response to photons. The response of the microenvironment to charged particles is therefore under scrutiny, and both the damage in the target and non-target tissues are relevant. The role of individual susceptibility in therapy and risk is obviously a major topic in radiation research in general, and for ion radiobiology as well. Particle radiobiology is therefore now entering into a new phase, where beyond RBE, the tissue response is considered. These results may open new applications for both cancer therapy and protection in deep space.
Collapse
Affiliation(s)
- M Durante
- GSI Helmholtz Center for Heavy Ion Research, Biophysics Department, Darmstadt, Germany
| |
Collapse
|
190
|
Gerweck LE, Huang P, Lu HM, Paganetti H, Zhou Y. Lifetime increased cancer risk in mice following exposure to clinical proton beam-generated neutrons. Int J Radiat Oncol Biol Phys 2014; 89:161-6. [PMID: 24725699 DOI: 10.1016/j.ijrobp.2014.01.057] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 01/29/2014] [Accepted: 01/30/2014] [Indexed: 11/26/2022]
Abstract
PURPOSE To evaluate the life span and risk of cancer following whole-body exposure of mice to neutrons generated by a passively scattered clinical spread-out Bragg peak (SOBP) proton beam. METHODS AND MATERIALS Three hundred young adult female FVB/N mice, 152 test and 148 control, were entered into the experiment. Mice were placed in an annular cassette around a cylindrical phantom, which was positioned lateral to the mid-SOBP of a 165-MeV, clinical proton beam. The average distance from the edge of the mid-SOBP to the conscious active mice was 21.5 cm. The phantom was irradiated with once-daily fractions of 25 Gy, 4 days per week, for 6 weeks. The age at death and cause of death (ie, cancer and type vs noncancer causes) were assessed over the life span of the mice. RESULTS Exposure of mice to a dose of 600 Gy of proton beam-generated neutrons, reduced the median life span of the mice by 4.2% (Kaplan-Meier cumulative survival, P=.053). The relative risk of death from cancer in neutron exposed versus control mice was 1.40 for cancer of all types (P=.0006) and 1.22 for solid cancers (P=.09). For a typical 60 Gy dose of clinical protons, the observed 22% increased risk of solid cancer would be expected to decrease by a factor of 10. CONCLUSIONS Exposure of mice to neutrons generated by a proton dose that exceeds a typical course of radiation therapy by a factor of 10, resulted in a statistically significant increase in the background incidence of leukemia and a marginally significant increase in solid cancer. The results indicate that the risk of out-of-field second solid cancers from SOBP proton-generated neutrons and typical treatment schedules, is 6 to 10 times less than is suggested by current neutron risk estimates.
Collapse
Affiliation(s)
- Leo E Gerweck
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
| | - Peigen Huang
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
| | - Hsiao-Ming Lu
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
| | - Yenong Zhou
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
| |
Collapse
|
191
|
Abstract
Proton therapy is a novel technique for treating pediatric malignancies. As a tool to reduce normal-tissue dose, it has the potential to decrease late toxicity. Although proton therapy has been used for over five decades, most pediatric dosimetry studies and clinical series have been published over the last 10 years. The purpose of this article is to review the physical, radiobiological and economic rationales for proton therapy in pediatric CNS malignancies, and provide an overview of the current challenges and future direction of research and utilization of this approach.
Collapse
Affiliation(s)
- Radhika Sreeraman
- Department of Radiation Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| | - Daniel J Indelicato
- University of Florida Proton Therapy Institute, 2015 North Jefferson Street, Jacksonville, FL 32206, USA
| |
Collapse
|
192
|
[The issue of low doses in radiation therapy and impact on radiation-induced secondary malignancies]. Bull Cancer 2014; 100:1333-42. [PMID: 24257106 DOI: 10.1684/bdc.2013.1855] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Several studies have well documented that the risk of secondary neoplasms is increasing among patients having received radiation therapy as part of their primary anticancer treatment. Most frequently, radiation-induced neoplasms occur in volume exposed to high doses. However, the impact of "low" doses (<5 Gy) in radiation-induced carcinogenesis should be clinically considered because modern techniques of intensity-modulated radiation therapy (IMRT) or stereotactic irradiation significantly increase tissue volumes receiving low doses. The risk inherent to these technologies remains uncertain and estimates closely depend on the chosen risk model. According to the (debated) linear no-threshold model, the risk of secondary neoplasms could be twice higher with IMRT, as compared to conformal radiation therapy. It seems that only proton therapy could decrease both high and low doses delivered to non-target volumes. Except for pediatric tumors, for which the unequivocal risk of second malignancies (much higher than in adults) should be taken into account, epidemiological data suggest that the risk of secondary cancer related to low doses could be very low, even negligible in some cases. However, clinical follow-up remains insufficient and a marginal increase in secondary tumors could counterbalance the benefit of a highly sophisticated irradiation technique. It therefore remains necessary to integrate the potential risk of new irradiation modalities in a risk-adapted strategy taking into account therapeutic objectives but also associated risk factors, such as age (essentially), chemotherapy, or life style.
Collapse
|
193
|
Buchsbaum JC, McDonald MW, Johnstone PAS, Hoene T, Mendonca M, Cheng CW, Das IJ, McMullen KP, Wolanski MR. Range modulation in proton therapy planning: a simple method for mitigating effects of increased relative biological effectiveness at the end-of-range of clinical proton beams. Radiat Oncol 2014; 9:2. [PMID: 24383792 PMCID: PMC3904459 DOI: 10.1186/1748-717x-9-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Accepted: 12/23/2013] [Indexed: 01/28/2023] Open
Abstract
Background The increase in relative biological effectiveness (RBE) of proton beams at the distal edge of the spread out Bragg peak (SOBP) is a well-known phenomenon that is difficult to quantify accurately in vivo. For purposes of treatment planning, disallowing the distal SOBP to fall within vulnerable tissues hampers sparing to the extent possible with proton beam therapy (PBT). We propose the distal RBE uncertainty may be straightforwardly mitigated with a technique we call “range modulation”. With range modulation, the distal falloff is smeared, reducing both the dose and average RBE over the terminal few millimeters of the SOBP. Methods One patient plan was selected to serve as an example for direct comparison of image-guided radiotherapy plans using non-range modulation PBT (NRMPBT), and range-modulation PBT (RMPBT). An additional plan using RMPBT was created to represent a re-treatment scenario (RMPBTrt) using a vertex beam. Planning statistics regarding dose, volume of the planning targets, and color images of the plans are shown. Results The three plans generated for this patient reveal that in all cases dosimetric and device manufacturing advantages are able to be achieved using RMPBT. Organ at risk (OAR) doses to critical structures such as the cochleae, optic apparatus, hypothalamus, and temporal lobes can be selectively spared using this method. Concerns about the location of the RBE that did significantly impact beam selection and treatment planning no longer have the same impact on the process, allowing these structures to be spared dose and subsequent associated issues. Conclusions This present study has illustrated that RMPBT can improve OAR sparing while giving equivalent coverage to target volumes relative to traditional PBT methods while avoiding the increased RBE at the end of the beam. It has proven easy to design and implement and robust in our planning process. The method underscores the need to optimize treatment plans in PBT for both traditional energy dose in gray (Gy) and biologic dose (RBE).
Collapse
Affiliation(s)
- Jeffrey C Buchsbaum
- Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
194
|
Bekelman JE, Schultheiss T, Berrington De Gonzalez A. Subsequent malignancies after photon versus proton radiation therapy. Int J Radiat Oncol Biol Phys 2013; 87:10-2. [PMID: 23810521 DOI: 10.1016/j.ijrobp.2013.05.016] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Accepted: 05/09/2013] [Indexed: 12/01/2022]
|